New Zealand based Neuren buys into brain disorder drug
Auckland New Zealand based Neuren Pharmaceuticals has bought a US drug company to target a multibillion-dollar market for treating post stroke, Alzheimer’s, Parkinson’s and traumatic brain injury caused depression. The purchase of Washington DC-based Hamilton Pharmaceuticals will get Neuren the license to a compound called Motiva. Motiva is being developed for psychological and cognitive disorders caused by stroke, traumatic brain injury, Alzheimer's and Parkinson's diseases.
Continue reading "New Zealand based Neuren buys into brain disorder drug" »
